Nuala A Helsby

List of Publications by Year
in descending order

76 papers	2,666 citations	218381 26 h-index	197535 49 g-index
79 all docs	79 docs citations	79 times ranked	4535 citing authors

#	Article	IF	Citations
1	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 2019, 176, S297-S396.	2.7	423
2	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 2021, 178, S313-S411.	2.7	320
3	Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEXÂ® ADME PGx Panel for Pharmacogenomic Profiling. Frontiers in Pharmacology, 2016, 7, 1.	1.6	231
4	The activation of the biguanide antimalarial proguanil coâ€segregates with the mephenytoin oxidation polymorphismâ€a panel study.. British Journal of Clinical Pharmacology, 1991, 31, 689-692.	1.1	144
5	The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. European Journal of Clinical Pharmacology, 1988, 35, 681-684.	0.8	83
6	The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.. British Journal of Clinical Pharmacology, 1990, 30, 593-598.	1.1	75
7	2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. British Journal of Cancer, 2004, 90, 1084-1092.	2.9	71
8	Metabolomic Analysis Identifies Inflammatory and Noninflammatory Metabolic Effects of Genetic Modification in a Mouse Model of Crohnâ€™s Disease. Journal of Proteome Research, 2010, 9, 1965-1975.	1.8	64
9	In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.. British Journal of Clinical Pharmacology, 1990, 30, 287-291.	1.1	62
10	Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards. Radiation Research, 2007, 167, 625-636.	0.7	61
11	Effect of Nitroreduction on the Alkylating Reactivity and Cytotoxicity of the 2,4-Dinitrobenzamide-5-aziridine CB 1954 and the Corresponding Nitrogen Mustard SN 23862:Â Distinct Mechanisms of Bioreductive Activation. Chemical Research in Toxicology, 2003, 16, 469-478.	1.7	59
12	Nontargeted Urinary Metabolite Profiling of a Mouse Model of Crohnâ€™s Disease. Journal of Proteome Research, 2009, 8, 2045-2057.	1.8	59
13	Using metabolomic analysis to understand inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 1021-1029.	0.9	56
14	Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Research, 2002, 62, 1425-32.	0.4	56
15	Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 571-577.	1.3	50
16	CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. British Journal of Cancer, 2008, 99, 1251-1255.	2.9	46
17	The combined impact of <i>CYP2C19</i> and <i>CYP2B6</i> pharmacogenetics on cyclophosphamide bioactivation. British Journal of Clinical Pharmacology, 2010, 70, 844-853.	1.1	46
18	Trypanocidal Activity of Aziridinyl Nitrobenzamide Prodrugs. Antimicrobial Agents and Chemotherapy, 2010, 54, 4246-4252.	1.4	42

#	Article	IF	Citations
19	Inhibition of Mouse and Human CYP 1A- and 2E1-dependent Substrate Metabolism by the Isoflavonoids Genistein and Equol. Food and Chemical Toxicology, 1998, 36, 375-382.	1.8	41
20	The multiple dose pharmacokinetics of proguanil.. British Journal of Clinical Pharmacology, 1993, 35, 653-656.	1.1	40
21	The isoflavones equol and genistein do not induce xenobiotic-metabolizing enzymes in mouse and in human cells. Xenobiotica, 1997, 27, 587-596.	0.5	39
22	Antimutagenic effects of wheat bran diet through modification of xenobiotic metabolising enzymes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 454, 77-88.	0.4	39
23	The role of Sâ€mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.. British Journal of Clinical Pharmacology, 1995, 39, 441-444.	1.1	34
24	Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin. Journal of Medicinal Chemistry, 2013, 56, 9542-9555.	2.9	30
25	Aziridinyldinitrobenzamides:Â Synthesis and Structureâˆ'Activity Relationships for Activation byE.coliNitroreductase. Journal of Medicinal Chemistry, 2004, 47, 3295-3307.	2.9	29
26	Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19. Frontiers in Genetics, 2012, 3, 206.	1.1	28
27	The importance of both <i>CYP2C19</i> and <i>CYP2B6</i> germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. British Journal of Clinical Pharmacology, 2019, 85, 1925-1934.	1.1	28
28	Metabolic Activation of the Antitumor Drug 5-(Aziridin-1-yl)-2,4-Dinitrobenzamide (CB1954) by NO Synthases. Chemical Research in Toxicology, 2008, 21, 836-843.	1.7	25
29	Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamatesâ€Šâ€. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 1601-1608.	1.3	21
30	Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology, 2005, 216, 129-139.	2.0	20
31	Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. European Journal of Pharmaceutical Sciences, 2016, 81, 36-41.	1.9	20
32	Comparative bioactivation of the novel antiâ€tuberculosis agent PAâ€824 in <i>Mycobacteria</i> and a subcellular fraction of human liver. British Journal of Pharmacology, 2011, 162, 226-236.	2.7	19
33	Can in vitro drug metabolism studies with human tissue replace in vivo animal studies?. Environmental Toxicology and Pharmacology, 2006, 21, 184-190.	2.0	17
34	Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. Pharmacogenomics, 2012, 13, 83-89.	0.6	17
35	CYP2C19 genotypeâ€"phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemotherapy and Pharmacology, 2014, 73, 651-655.	1.1	16
36	The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population. Pain Medicine, 2019, 20, 1803-1814.	0.9	16

#	Article	IF	Citations
37	A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Human Genomics, 2008, 3, 17.	1.4	15
38	CYP2C19 and CYP2D6 genotypes in Pacific peoples. British Journal of Clinical Pharmacology, 2016, 82, 1303-1307.	1.1	15
39	Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat. Toxicology, 2007, 240, 70-85.	2.0	11
40	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. Oncology and Therapy, 2021, 9, 541-556.	1.0	11
41	Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. British Journal of Clinical Pharmacology, 2010, 69, 516-519.	1.1	10
42	Metabolomic analysis reveals differences in urinary excretion of kiwifruitâ€derived metabolites in a mouse model of inflammatory bowel disease. Molecular Nutrition and Food Research, 2011, 55, 1900-1904.	1.5	10
43	The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status. American Journal of Hematology, 2011, 86, 383-384.	2.0	10
44	Which CYP2B6 Variants Have Functional Consequences for Cyclophosphamide Bioactivation?: TABLE 1. Drug Metabolism and Disposition, 2012, 40, 635-637.	1.7	10
45	Incidence and investigation of potential risk-factors for clozapine-associated myocarditis and cardiomyopathy in a New Zealand cohort. Psychiatry Research, 2021, 299, 113873.	1.7	10
46	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 88, 533-542.	1.1	10
47	Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer <i>N</i>-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugs. Drug Metabolism and Disposition, 2008, 36, 353-360.	1.7	9
48	Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects. Biomedical Reports, 2014, 2, 265-269.	0.9	9
49	Evaluating Aziridinyl Nitrobenzamide Compounds as Leishmanicidal Prodrugs. Antimicrobial Agents and Chemotherapy, 2014, 58, 370-377.	1.4	9
50	Unravelling the role of <scp>SNM</scp>1 in the <scp>DNA</scp> repair system of <scp><i>T</i></scp><i>rypanosoma brucei</i>. Molecular Microbiology, 2015, 96, 827-838.	1.2	9
51	A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes. Cancer Chemotherapy and Pharmacology, 2021, 88, 755-769.	1.1	9
52	Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?. Cancer Chemotherapy and Pharmacology, 2010, 66, 405-407.	1.1	8
53	The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 417-425.	0.6	8
54	Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease. Proceedings of the Western Pharmacology Society, 2008, 51, 5-10.	0.1	7

#	Article	IF	Citations
55	High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy and Pharmacology, 2016, 77, 195-204.	1.1	6
56	Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics, 2018, 28, 153-164.	0.7	6
57	Hydrolysis of Dinitrobenzamide Phosphate Prodrugs: The Role of Alkaline Phosphatase. Drug Metabolism and Drug Interactions, 2009, 24, 1-16.	0.3	4
58	Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers. Oncology Letters, 2014, 7, 2035-2040.	0.8	4
59	Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. Therapeutic Drug Monitoring, 2018, 40, 495-502.	1.0	4
60	A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells. Scientific Reports, 2019, 9, 18912.	1.6	4
61	A caseâ€“control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidineâ€induced gastrointestinal toxicity. British Journal of Clinical Pharmacology, 2020, 86, 155-164.	1.1	4
62	The Association Between Heterozygosity forUGT1A1*6,UGT1A1*28, and Variation in the Serum Total-Bilirubin Level in Healthy Young Japanese Adults. Genetic Testing and Molecular Biomarkers, 2013, 17, 464-469.	0.3	3
63	Indirect regulation of CYP2C19 gene expression via DNA methylation. Xenobiotica, 2018, 48, 781-792.	0.5	3
64	Comparison of a thymine challenge test and endogenous uracilâ€“dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer Chemotherapy and Pharmacology, 2021, 87, 711-716.	1.1	3
65	Cytochrome P450 in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	3
66	Inter-individual variation in the metabolic activation of the antimalarial biguanides. Parasitology Today, 1991, 7, 120-123.	3.1	2
67	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ASSAY FOR THE DETERMINATION OF A FLUORINATED ANALOGUE OF THALIDOMIDE, N-(2,6-DIOXOPIPERIDIN-3-YL)-3,4,5,6-TETRAFLUOROPHTHALAMIC ACID, AND LENALIDOMIDE. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 83-92.	0.5	2
68	A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemotherapy and Pharmacology, 2019, 84, 739-748.	1.1	2
69	Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 817-820.	0.6	1
70	Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes. Xenobiotica, 2021, 51, 1188-1198.	0.5	1
71	Cytochrome P450 (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
72	Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans?. New Zealand Medical Journal, 2010, 123, 37-41.	0.5	1

#	Article	IF	Citations
73	Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. New Zealand Medical Journal, 2021, 134, 120-128.	0.5	1
74	CYP2 family: physiological enzymes subset in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
75	Transport of 5-fluorouracil into primary human cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-8.	0.0	0
76	Human liver degradation of 5-fluorouracil: endogenous uracil may result in phenoconversion of dihydropyrimidine dehydrogenase activity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-1.	0.0	0